Lundbeckfond Invest A/S 4
4 · IO Biotech, Inc. · Filed Nov 12, 2021
Insider Transaction Report
Form 4
IO Biotech, Inc.IOBT
Lundbeckfond Invest A/S
Director10% Owner
Transactions
- Conversion
Common Stock
[F1]2021-11-09+2,014,161→ 2,014,161 total - Conversion
Common Stock
[F2]2021-11-09+1,892,434→ 3,906,595 total - Purchase
Common Stock
2021-11-09$14.00/sh+2,142,857$29,999,998→ 6,049,452 total - Conversion
Series B Preferred Stock
[F1]2021-11-09−219,595→ 0 total→ Common Stock (2,014,161 underlying) - Conversion
Series C Preferred Stock
[F2]2021-11-09−150,534→ 0 total→ Common Stock (1,892,434 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series B Preferred Stock had no expiration date.
- [F2]Upon the closing of the IPO, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
Signature
Lundbeckfond Invest A/S, by: /s/ Brian Burkavage, Attorney-in-Fact for Christian Elling, Managing Partner, and Lene Skole, Chief Executive Officer|2021-11-12